Novavax, Inc. (NASDAQ:NVAX) Shares Acquired by Virtus ETF Advisers LLC

Virtus ETF Advisers LLC grew its position in Novavax, Inc. (NASDAQ:NVAX) by 77.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,765 shares of the biopharmaceutical company’s stock after purchasing an additional 16,881 shares during the period. Virtus ETF Advisers LLC’s holdings in Novavax were worth $312,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Dauntless Investment Group LLC acquired a new position in shares of Novavax in the 4th quarter valued at about $698,000. Syon Capital LLC acquired a new position in shares of Novavax in the 4th quarter valued at about $128,000. Hsbc Holdings PLC lifted its stake in shares of Novavax by 69.4% in the 4th quarter. Hsbc Holdings PLC now owns 17,931 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 7,344 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Novavax by 65.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 29,390 shares of the biopharmaceutical company’s stock worth $236,000 after acquiring an additional 11,632 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its position in Novavax by 14.3% during the 4th quarter. MetLife Investment Management LLC now owns 93,447 shares of the biopharmaceutical company’s stock worth $751,000 after acquiring an additional 11,725 shares in the last quarter. 53.04% of the stock is owned by institutional investors and hedge funds.

Novavax Stock Down 5.7 %

NVAX stock opened at $6.67 on Monday. Novavax, Inc. has a 52-week low of $4.10 and a 52-week high of $23.86. The stock’s 50 day moving average is $7.13 and its two-hundred day moving average is $8.32. The company has a market capitalization of $1.07 billion, a PE ratio of -2.95, a P/E/G ratio of 2.85 and a beta of 3.15.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.24. The firm had revenue of $88.31 million during the quarter, compared to the consensus estimate of $85.48 million. During the same quarter last year, the firm posted ($1.44) earnings per share. As a group, sell-side analysts anticipate that Novavax, Inc. will post -1.46 EPS for the current year.

Wall Street Analyst Weigh In

NVAX has been the topic of several recent research reports. TD Cowen raised Novavax to a “hold” rating in a research report on Thursday, February 27th. BTIG Research initiated coverage on Novavax in a research report on Friday, February 28th. They set a “buy” rating and a $19.00 price target on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $18.00.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.